UY31101A1 - Composición antigénica liofilizada - Google Patents

Composición antigénica liofilizada

Info

Publication number
UY31101A1
UY31101A1 UY31101A UY31101A UY31101A1 UY 31101 A1 UY31101 A1 UY 31101A1 UY 31101 A UY31101 A UY 31101A UY 31101 A UY31101 A UY 31101A UY 31101 A1 UY31101 A1 UY 31101A1
Authority
UY
Uruguay
Prior art keywords
compositions
liofilized
antigenic
composition
lyophilized
Prior art date
Application number
UY31101A
Other languages
English (en)
Inventor
Dominique Ingrid Lemoine
Francoise Mathilde Maurice Hogge
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2007/055037 external-priority patent/WO2007137986A2/en
Priority claimed from GB0723044A external-priority patent/GB0723044D0/en
Priority claimed from GB0723900A external-priority patent/GB0723900D0/en
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of UY31101A1 publication Critical patent/UY31101A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención proporciona composiciones liofilizadas que comprenden un antígeno y un agonista del receptor del tipo Toll (TRL) 9. Tales composiciones se pueden reconstituir en composiciones inmunogénicas para uso en vacunación con un vehículo seleccionado entre el grupo de vehículos particulados constituidos por liposomas, sales minerales, emulsiones, polímeros e ISCOM. Los procedimientos de preparación de composiciones inmunogénicas a partir de composiciones liofilizadas de la invención y uso de la misma en la inmunización también se proporcionan en el presente documento.
UY31101A 2007-05-24 2008-05-22 Composición antigénica liofilizada UY31101A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2007/055037 WO2007137986A2 (en) 2006-05-26 2007-05-24 Vaccination against cancer
GB0723044A GB0723044D0 (en) 2007-11-23 2007-11-23 Lyophillised antigen composition
GB0723900A GB0723900D0 (en) 2007-12-06 2007-12-06 Lyophillised antigen composition

Publications (1)

Publication Number Publication Date
UY31101A1 true UY31101A1 (es) 2009-01-05

Family

ID=39714209

Family Applications (1)

Application Number Title Priority Date Filing Date
UY31101A UY31101A1 (es) 2007-05-24 2008-05-22 Composición antigénica liofilizada

Country Status (23)

Country Link
US (2) US20090035360A1 (es)
EP (3) EP2148697B1 (es)
JP (1) JP5331105B2 (es)
KR (2) KR101238795B1 (es)
CN (1) CN101678091A (es)
AR (1) AR066676A1 (es)
AU (1) AU2008252911B2 (es)
BR (1) BRPI0811228A2 (es)
CA (1) CA2687632C (es)
CL (1) CL2008001491A1 (es)
CY (1) CY1113446T1 (es)
DK (1) DK2148697T3 (es)
EA (3) EA201300101A1 (es)
ES (1) ES2395333T3 (es)
HR (1) HRP20121019T1 (es)
MX (1) MX2009012381A (es)
PE (1) PE20090281A1 (es)
PL (1) PL2148697T3 (es)
PT (1) PT2148697E (es)
SI (1) SI2148697T1 (es)
TW (1) TW200911304A (es)
UY (1) UY31101A1 (es)
WO (1) WO2008142133A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200726479A (en) 2005-04-12 2007-07-16 Univ Duke Method of inducing neutralizing antibodies to human immunodeficiency virus
JP2009511637A (ja) 2005-10-17 2009-03-19 スローン−ケターリング インスティチュート フォー キャンサー リサーチ Ｈｌａクラスｉｉ結合ｗｔ１ペプチド及びその組成物、並びにその作成方法
CA2645766A1 (en) 2006-04-10 2007-10-25 Sloan Kettering Institute For Cancer Research Immunogenic wt-1 peptides and methods of use thereof
WO2008127651A1 (en) * 2007-04-13 2008-10-23 Duke University Method of inducing neutralizing antibodies to human immunodeficiency virus
CA2757240A1 (en) * 2009-04-03 2010-10-07 Duke University Formulation for inducing broadly reactive neutralizing anti-hiv antibodies
GB0910045D0 (en) * 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
GB0910046D0 (en) * 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
CN103260642B (zh) * 2010-12-14 2018-03-16 葛兰素史密丝克莱恩生物有限公司 分枝杆菌抗原组合物
JP2014529338A (ja) * 2011-07-22 2014-11-06 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Ｐｒａｍｅの精製
CN108676069A (zh) 2012-01-13 2018-10-19 纪念斯隆凯特林癌症中心 免疫原性wt-1肽及其使用方法
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
CN110078813B (zh) 2013-01-15 2023-03-28 纪念斯隆凯特林癌症中心 免疫原性wt-1肽和其使用方法
US10076567B2 (en) 2013-09-27 2018-09-18 Duke University MPER-liposome conjugates and uses thereof
KR102411781B1 (ko) * 2013-12-31 2022-06-22 인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이) 단일 바이알 백신 제형
RU2016141621A (ru) * 2014-03-25 2018-04-25 Зэ Гавермент Оф Зэ Юнайтед Стэйтс Оф Америка Эс Репрезентед Бай Зэ Секретари Оф Зэ Арми Способы усиления эффективности иммуностимуляции адсорбированных на соли алюминия вакцин
SG11201803594TA (en) 2015-11-06 2018-05-30 Adjuvance Technologies Inc Triterpene saponin analogues
WO2018104313A1 (en) 2016-12-07 2018-06-14 Glaxosmithkline Biologicals Sa Novel process
CA3075822A1 (en) * 2017-10-16 2019-04-25 Adjuvance Technologies, Inc. Triterpene saponin analogues
CN112673054A (zh) 2018-07-19 2021-04-16 葛兰素史密丝克莱恩生物有限公司 用于制备干燥多糖的方法

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US666A (en) 1838-04-02 Sfbing-bock for coagh and railroad-gab
US5827A (en) 1848-10-03 Improved table-cutlery
US6222020B1 (en) 1987-01-07 2001-04-24 Imperial Cancer Research Technology Limited Antigens derived from the core protein of the human mammary epithelial mucin
WO1988005054A1 (en) 1987-01-07 1988-07-14 Imperial Cancer Research Technology Limited Probe
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4963484A (en) 1988-01-29 1990-10-16 Dana-Farber Cancer Institute, Inc. Genetically engineered polypeptides with determinants of the human DF3 breast carcinoma-associated antigen
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5256643A (en) * 1990-05-29 1993-10-26 The Government Of The United States Human cripto protein
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
US5744144A (en) 1993-07-30 1998-04-28 University Of Pittsburgh University Patent Committee Policy And Procedures Synthetic multiple tandem repeat mucin and mucin-like peptides, and uses thereof
US5688506A (en) 1994-01-27 1997-11-18 Aphton Corp. Immunogens against gonadotropin releasing hormone
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
ATE328890T1 (de) 1994-07-15 2006-06-15 Univ Iowa Res Found Immunomodulatorische oligonukleotide
US5830753A (en) 1994-09-30 1998-11-03 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof.
US5981215A (en) 1995-06-06 1999-11-09 Human Genome Sciences, Inc. Human criptin growth factor
US5666153A (en) * 1995-10-03 1997-09-09 Virtual Shopping, Inc. Retractable teleconferencing apparatus
US6130043A (en) 1997-05-02 2000-10-10 Abbott Laboratories Reagents and methods useful for detecting diseases of the prostate
JP2001517638A (ja) * 1997-09-25 2001-10-09 スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ 小細胞肺癌に対するフコーシルｇｍ−１−ｋｌｈ接合体ワクチン
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
CA2331769A1 (en) 1998-06-22 1999-12-29 Incyte Pharmaceuticals, Inc. Prostate cancer-associated genes
DK1104306T3 (da) * 1998-08-10 2006-05-22 Antigenics Inc Præparater af CpG- og saponinadjuvanser og fremgangsmåder til anvendelse deraf
US20030235557A1 (en) * 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
ES2348708T3 (es) 1999-01-29 2010-12-13 Corixa Corporation Proteinas de fusion de her-2/neu.
AU756398B2 (en) 1999-03-11 2003-01-09 Smithkline Beecham Biologicals (Sa) Novel compounds
US6949520B1 (en) * 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
CZ303468B6 (cs) 2000-02-23 2012-10-03 Smithkline Beecham Biologicals S. A. Imunogenní smes a farmaceutická smes
US20040022814A1 (en) * 2000-06-15 2004-02-05 O'hagan Derek Microparticles with adsorbent surfaces, methods of making same, and uses thereof
GB0022742D0 (en) * 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
ATE384072T1 (de) 2000-09-26 2008-02-15 Idera Pharmaceuticals Inc Modulation der immunostimulatorischen aktivität von immunostimulierenden oligonukleotidanaloga durch positionelle chemische veränderungen
US20030031684A1 (en) 2001-03-30 2003-02-13 Corixa Corporation Methods for the production of 3-O-deactivated-4'-monophosphoryl lipid a (3D-MLA)
US7553494B2 (en) * 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
EP1427826B1 (en) 2001-09-20 2011-04-20 Glaxo Group Limited HIV- RT-nef-Gag codon optimised DNA vaccines
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
GB0218821D0 (en) * 2002-08-13 2002-09-18 Glaxosmithkline Biolog Sa Novel compositions
AU2003297499A1 (en) * 2002-12-23 2004-07-22 City Of Hope Modified vaccinia ankara expressing p53 in cancer immunotherapy
GB0323968D0 (en) 2003-10-13 2003-11-19 Glaxosmithkline Biolog Sa Immunogenic compositions
EP1547581A1 (en) * 2003-12-23 2005-06-29 Vectron Therapeutics AG Liposomal vaccine for the treatment of human hematological malignancies
GB0409940D0 (en) * 2004-05-04 2004-06-09 Glaxosmithkline Biolog Sa Vaccine
GB0411411D0 (en) 2004-05-21 2004-06-23 Glaxosmithkline Biolog Sa Vaccines
EA200700017A1 (ru) * 2004-06-12 2009-06-30 Ле Сантр Насьональ Де Ля Решерш Сьентифик ( Снрс ) Способ усиления иммунного ответа на вакцину
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
EP1858526A1 (en) 2005-03-02 2007-11-28 Solbec Pharmaceuticals Limited Glycoalkaloid and tlr agonist combinations and various uses thereof
SG162817A1 (en) * 2005-06-17 2010-07-29 Mannkind Corp Methods and compositions.to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma

Also Published As

Publication number Publication date
US8557247B2 (en) 2013-10-15
AR066676A1 (es) 2009-09-02
CY1113446T1 (el) 2016-06-22
ES2395333T3 (es) 2013-02-12
KR20110091817A (ko) 2011-08-12
JP2010527964A (ja) 2010-08-19
EP2489367A1 (en) 2012-08-22
SI2148697T1 (sl) 2013-01-31
CA2687632A1 (en) 2008-11-27
EA201300102A1 (ru) 2014-02-28
JP5331105B2 (ja) 2013-10-30
EP2148697A1 (en) 2010-02-03
TW200911304A (en) 2009-03-16
PE20090281A1 (es) 2009-03-28
PT2148697E (pt) 2012-12-24
DK2148697T3 (da) 2012-12-17
HRP20121019T1 (hr) 2013-01-31
KR101238795B1 (ko) 2013-03-07
AU2008252911B2 (en) 2013-09-05
BRPI0811228A2 (pt) 2014-10-21
CA2687632C (en) 2013-01-15
EP2148697B1 (en) 2012-10-03
WO2008142133A1 (en) 2008-11-27
KR20100017519A (ko) 2010-02-16
CN101678091A (zh) 2010-03-24
EP2476431A1 (en) 2012-07-18
PL2148697T3 (pl) 2013-02-28
EA201300101A1 (ru) 2014-02-28
CL2008001491A1 (es) 2008-11-28
AU2008252911A1 (en) 2008-11-27
MX2009012381A (es) 2009-12-01
EA200901434A1 (ru) 2010-06-30
US20090035360A1 (en) 2009-02-05
EA018201B1 (ru) 2013-06-28
US20110059163A1 (en) 2011-03-10

Similar Documents

Publication Publication Date Title
UY31101A1 (es) Composición antigénica liofilizada
BRPI0509606A (pt) emulsões de óleo-em-água microfluidizadas e composições para vacinas
AR078085A1 (es) Peptidos tau antigenicos y usos de los mismos
CY1118492T1 (el) Φαρμακοτεχνικες μορφες εμβολιου norovirus
DOP2013000128A (es) Uso de células t modificadas con un receptor de antígeno quimérico para tratar el cáncer
BR112018004242A2 (pt) composições de vacina que possuem estabilidade e imunogenicidade aumentadas
CO6260103A2 (es) Composiciones que comprenden antigenos neumococidos
GB201009273D0 (en) Novel vaccine
BR112013008700B8 (pt) Molécula de rna auto-replicante, partícula de replicon de alfavírus, composição, molécula de dna recombinante, uso da molécula de rna auto-replicante
MX2013001527A (es) Nuevas vacunas adyuvantes en base a adyuvantes de orientacion para anticuerpos directamente hacia celulas presentadoras de antigenos.
AR085633A1 (es) Coadyuvantes basados en anticuerpos que son dirigidos directamente a las celulas presentadoras en antigenos
DOP2013000029A (es) Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos
DE602005025531D1 (de) Saccharid-konjugatvakzine
SI2484375T1 (en) A vaccine composition comprising a synthetic adjuvant
UY28256A1 (es) Emulsiones de aceite en agua microfludizadas y composiciones de vacunas
EA201100268A1 (ru) Вакцина
MY150706A (en) Immunogenic substances comprising a polyinosinic acid-polycytidilic acid based adjuvant
DOP2009000167A (es) Vacuna
MX2014005372A (es) Molecula portadora que comprende un antigeno spr0096 y un spr2021.
BRPI0915076A2 (pt) composições de vacina, composição imunogênica, método para expressão dos antígenos quiméricos de hpv-hbsag supramencionados, composição farmacêutica, método para ocasionar resposta de anticorpo protetor para composição antigênica e/ou resposta de célula t citotóxica, uso das formulações antigênicas supramencionadas.
AR102548A1 (es) Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y uso
AR089068A1 (es) Composiciones para el cuidado del cabello que contiene un polimero de aminosilicona
TN2009000195A1 (en) Prime boost canine leishmania vaccine
TW200833709A (en) Archaeal polar lipid aggregates for administration to animals
AR082281A1 (es) Vectores de parapoxvirus

Legal Events

Date Code Title Description
DESI Application deemed to be withdrawn

Effective date: 20120613